Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK16149 Combined with L-carnitine in Diabetic Peripheral Neuralgia
NCT06122012Recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of crisugabalin besilate in diabetic polyneuropathy (DPN) (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Efficacy and Safety of HSK16149 combination at 12 weeks. Started May 2023; status: recruiting.
02
Drugs
crisugabalin besilate
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT06122012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122012.